p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
about
Triple negative breast cancer: looking for the missing link between biology and treatmentsTrial Watch-Immunostimulation with cytokines in cancer therapyBody mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.Flavopiridol: An Old Drug With New Perspectives? Implication for Development of New Drugs.Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyBody mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
P2860
Q26783122-5F6D6CED-2552-4EC9-AC5F-E22DEAD9627CQ28078725-EF14B08C-1C0A-4F32-BC44-40A54772C753Q36272043-BF85AB0F-F3F2-4318-8638-8A16DACC4E89Q36657326-CD9EF31D-7519-42B4-9A9B-C67D6B93E302Q38735367-90E4604D-E55C-4392-ADD7-FD551D493E16Q41630845-103E5CF4-A2A0-47B2-8430-A4D26E6C5463Q50035181-F1B2C8BA-CB49-46F4-9BCC-1C54E674B45AQ51310879-BD923AF0-18F7-4D1F-B67B-D51ED7D5060FQ52911366-682D66F8-9C12-4E7B-8450-8F823AABD980
P2860
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
p53 status as effect modifier ...... ents treated with trastuzumab.
@ast
p53 status as effect modifier ...... ents treated with trastuzumab.
@en
p53 status as effect modifier ...... ents treated with trastuzumab.
@nl
type
label
p53 status as effect modifier ...... ents treated with trastuzumab.
@ast
p53 status as effect modifier ...... ents treated with trastuzumab.
@en
p53 status as effect modifier ...... ents treated with trastuzumab.
@nl
prefLabel
p53 status as effect modifier ...... ents treated with trastuzumab.
@ast
p53 status as effect modifier ...... ents treated with trastuzumab.
@en
p53 status as effect modifier ...... ents treated with trastuzumab.
@nl
P2093
P2860
P50
P356
P1433
P1476
p53 status as effect modifier ...... ients treated with trastuzumab
@en
P2093
Anna Di Benedetto
Antonio Giordano
Carmelina Antonella Iannuzzi
Claudio Botti
Domenico Sergi
Francesca Sperati
Irene Terrenato
Laura Pizzuti
Luca Esposito
Luigi Di Lauro
P2860
P304
10382-10392
P356
10.18632/ONCOTARGET.2060
P407
P577
2014-11-01T00:00:00Z